Cantargia reports Phase I/IIa data for cancer candidate CAN04
In October, Cantargia AB (SSE:CANTA) reported data from 1 patient in the Phase I/IIa CANFOUR trial showing that once-weekly IV CAN04 led to no serious adverse events. The first part of the open-label, European trial...
